Overview

Basal Cell Carcinoma Chemoprevention Trial

Status:
Not yet recruiting

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

This is an intent-to-treat, split-plot design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.

Phase:

Phase 3

Details

Lead Sponsor:

VA Office of Research and Development

Treatments:

Imiquimod